Tinea imbricata
Chapter 1:Certain infectious and parasitic diseases
ICD-10 B35.6 is a billable code used to indicate a diagnosis of tinea imbricata.
Tinea imbricata is a superficial fungal infection caused primarily by the dermatophyte Trichophyton concentricum. It is characterized by the presence of concentric, scaly rings that can appear on various parts of the body, particularly the trunk and extremities. The condition is endemic in certain tropical regions and is often associated with poor hygiene and close contact with infected individuals. Patients may present with pruritus, erythema, and scaling, which can lead to secondary bacterial infections if left untreated. Diagnosis is typically made through clinical examination and confirmed by fungal culture or KOH preparation. Treatment involves the use of topical antifungal agents such as clotrimazole or terbinafine, and in more severe cases, systemic antifungals like itraconazole may be necessary. Immunocompromised patients, such as those with HIV/AIDS or undergoing chemotherapy, are at a higher risk for more severe manifestations of tinea imbricata and may require more aggressive treatment and monitoring.
Detailed clinical notes including lesion description, location, and treatment response.
Patients presenting with ringworm-like lesions, recurrent infections, or those with a history of travel to endemic areas.
Consideration of differential diagnoses and the need for culture results to confirm the diagnosis.
Comprehensive history of immunocompromised status, previous infections, and treatment history.
Immunocompromised patients presenting with atypical or severe fungal infections.
Close monitoring of treatment efficacy and potential for systemic involvement.
When a biopsy is performed to confirm the diagnosis of tinea imbricata.
Document the reason for biopsy and findings.
Dermatology may require additional notes on lesion characteristics.
Tinea imbricata is primarily caused by the dermatophyte Trichophyton concentricum, which is often found in tropical regions.
Treatment typically involves topical antifungal agents, but systemic antifungals may be required for severe cases or in immunocompromised patients.
